 JUPITER, Fla., Feb. 07, 2022 GLOBE NEWSWIRE -- Dyadic International, Inc. Dyadic, or the Company NASDAQ: DYAI a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Companys CEO Mark Emalfarb will be presenting at the upcoming 2022 BIO CEO Investor Conference being held at the Marriott Marquis New York City February 14th -15th, and virtually through the 17th. 